Endocannabinoids and mental disorders

Handbook of Experimental Pharmacology

Volumn 231, Issue , 2015, Pages 261-283

  Rubino, Tiziana ^a   Zamberletti, Erica ^a,b   Parolaro, Daniela ^a,b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Zardi Gori Foundation   (Italy)

Author keywords

Autism; Bipolar disorder and suicidality; Depression; Endocannabinoid system anxiety; Posttraumatic stress disorder; Schizophrenia

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; AM 4113; ANANDAMIDE; BENZODIAZEPINE DERIVATIVE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; LIPOPROTEIN LIPASE; MESSENGER RNA; METHANANDAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N ARACHIDONOYL SEROTONIN; NESS 0327; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENCYCLIDINE; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602; VALPROIC ACID; VANILLOID RECEPTOR 1; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST;

AMNESIA; AMYGDALOID NUCLEUS; ANHEDONIA; ANXIETY DISORDER; AUTISM; AVERSIVE BEHAVIOR; BODY WEIGHT; CANNABIS USE; CB1R GENE; CHRONIC STRESS; CNR2 GENE; COPING BEHAVIOR; DEPRESSION; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ELEVATED PLUS MAZE TEST; ENZYME ACTIVATION; ENZYME INHIBITION; FRONTAL CORTEX; GENE; GENE DELETION; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IN VIVO STUDY; LEARNING DISORDER; LYMPHOCYTE; MENTAL DISEASE; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; OPEN FIELD TEST; PATHOPHYSIOLOGY; PERIAQUEDUCTAL GRAY MATTER; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SENSORY GATING; SIGNAL TRANSDUCTION; SOCIAL INTERACTION TEST; SUICIDAL IDEATION; TRANQUILIZING ACTIVITY; UPREGULATION; VENTRAL TEGMENTUM; ANIMAL; AUTISTIC DISORDER; BRAIN; DRUG EFFECTS; METABOLISM; MOOD DISORDERS; PSYCHOLOGY; PSYCHOTIC DISORDERS;

ANIMALS; AUTISTIC DISORDER; BRAIN; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; ENDOCANNABINOIDS; HUMANS; MOOD DISORDERS; PSYCHOTIC DISORDERS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION;

EID: 84942532132     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-319-20825-1_9     Document Type: Chapter

References (168)

1. Agrawal A, Nelson EC, Littlefield AK et al (2012) Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression. Arch Gen Psychiatry 69:732–740
2. Aguiar DC, Terzian AL, Guimarães FS et al (2009) Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl) 205:217–225
3. Akinshola BE, Chakrabarti A, Onaivi ES (1999) In-vitro and in-vivo action of cannabinoids. Neurochem Res 24:1233–1240
4. Aliczki M, Balogh Z, Tulogdi A et al (2012) The temporal dynamics of the effects of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature. Behav Pharmacol 23:348–357
5. Almeida V, Peres FF, Levin R et al (2014) Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain. Schizophr Res 153:150–159
6. Almeida-Santos AF, Gobira PH, Rosa LC et al (2013) Modulation of anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray. Behav Brain Res 252:10–17
7. Arevalo C, De Miguel R, Hernandez-Tristan R (2001) Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70:123–131
8. Aso E, Ozaita A, Valdizan EM et al (2008) BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 105:565–572
9. Azad SC, Eder M, Marsicano G et al (2003) Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10:116–128
10. Bagdy G, Juhasz G, Gonda X (2012) A new clinical evidence-based gene-environment interaction model of depression. Neuropsychopharmacol Hung 14:213–220
11. Beltramo M, de Fonseca FR, Navarro M et al (2000) Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 20:3401–3407
12. Beyer CE, Dwyer JM, Piesla MJ et al (2010) Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 39:148–155
13. Bhattacharyya S, Morrison PD, Fusar-Poli P et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764–774
14. Bilkei-Gorzo A, Racz I, Valverde O et al (2005) Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc Natl Acad Sci USA 102:15670–15675
15. Black MD, Stevens RJ, Rogacki N et al (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) 215:149–163
16. Bluett RJ, Gamble-George JC, Hermanson DJ et al (2014) Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry 4, e408
17. Bortolato M, Campolongo P, Mangieri RA et al (2006) Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31:2652–2659
18. Bortolato M, Mangieri RA, Fu J et al (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103–1110
19. Bosi DC, Hallak JE, Dursun SM et al (2003) Effects of cannabidiol on (s)-ketamine-induced psychopathology in healthy volunteers. J Psychopharmacology 17:55
20. Braida D, Limonta V, Malabarba L et al (2007) 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague–Dawley rats. Eur J Pharmacol 555:156–163
21. Burns HD, Van Laere K, Sanabria-Bohórquez S et al (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 104:9800–9805
22. Busquets-Garcia A, Puighermanal E, Pastor A et al (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479–486
23. Cameron C, Watson D, Robinson J (2014) Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol 34:559–564
24. Campos AC, Ferreira FR, Guimarães FS et al (2010) Facilitation of endocannabinoid effects in the ventral hippocampus modulates anxiety-like behaviors depending on previous stress experience. Neuroscience 167:238–246
25. Ceccarini J, De Hert M, Van Winkel R et al (2013) Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 79:304–312
26. Chavarriá-Siles I, Contreras-Rojas J, Hare E et al (2008) Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet BNeuropsychiatr Genet 147:279–284
27. Choi K, Le T, McGuire J et al (2012) Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J Psychiatr Res 46:882–889
28. Christensen R, Kristensen PK, Bartels EM et al (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706–1713
29. Cornelius JR, Kirisci L, Reynolds M et al (2010) PTSD contributes to teen and young adult cannabis use disorders. Addict Behav 35:91–94
30. Dalton VS, Long LE, Weickert CS et al (2011) Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 36:1620–1630
31. De Marchi N, De Petrocellis L, Orlando P et al (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 19:2–5
32. Dean B, Sundram S, Bradbury R et al (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15
33. Degroot A, Nomikos GG (2004) Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 20:1059–1064
34. Di Forti M, Morgan C, Dazzan P et al (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488–491
35. Dlugos A, Childs E, Stuhr KL et al (2012) Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 37:2416–2427
36. Domschke K, Dannlowski U, Ohrmann P et al (2008) Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 18:751–759
37. Dono LM, Currie PJ (2012) The cannabinoid receptor CB1 inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala. Neuropharmacology 62:192–199
38. Dubreucq S, Matias I, Cardinal P et al (2012) Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37:1885–1900
39. Eggan SM, Hashimoto T, Lewis DA (2008) Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65:772–784
40. Eggan SM, Stoyak SR, Verrico CD et al (2010) Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 35:2060–2071
41. Englund A, Morrison PD, Nottage J et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19–27
42. Ferretjans R, de Campos SM, Ribeiro-Santos R et al (2014) Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. Schizophr Res 156:254–260
43. Fraser GA (2009) The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 15:84–88
44. Gamble-George JC, Conger JR, Hartley ND et al (2013) Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology (Berl) 228:401–409
45. Garciá-Gutieŕrez MS, Garciá-Bueno B, Zoppi S et al (2012) Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol 165:951–964
46. Giuffrida A, Leweke FM, Gerth CW et al (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108–2114
47. Gomes FV, Casarotto PC, Resstel LB et al (2011) Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog Neuropsychopharmacol Biol Psychiatry 35:434–438
48. Gorzalka BB, Hill MN (2011) Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 35:1575–1585
49. Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261–267
50. Guidali C, Viganó D, Petrosino S et al (2011) Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int J Neuropsychopharmacol 14:17–28
51. Gunduz-Cinar O, Hill MN, McEwen BS et al (2013a) FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 34:637–644
52. Gunduz-Cinar O, MacPherson KP, Cinar R et al (2013b) Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stressreactivity. Mol Psychiatry 18:813–823
53. Haller J, Bakos N, Szirmay M et al (2002) The effects of genetic and pharmacological blockade ofthe CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395–1398
54. Haller J, Varga B, Ledent C et al (2004) Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behavior in mice. Eur J Neurosci 19:1906–1912
55. Haller J, Szirmai M, Varga B et al (2005) Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol 16:415–422
56. Haller J, Barna I, Barsvari B et al (2009) Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 204:607–616
57. Hauer D, Schelling G, Gola H et al (2013) Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One 8, e62741
58. Hill MN, Gorzalka BB (2005) Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 16:333–352
59. Hill MN, Tasker JG (2012) Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204:5–16
60. Hill MN, Patel S, Carrier EJ et al (2005) Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30:508–515
61. Hill MN, Carrier EJ, McLaughlin RJ et al (2008) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106:2322–2336
62. Hill MN, Miller GE, Carrier EJ et al (2009) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34:1257–1262
63. Hill MN, McLaughlin RJ, Pan B et al (2011) Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 31:10506–10515
64. Hill MN, Bierer LM, Makotkine I et al (2013a) Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 38:2952–2961
65. Hill MN, Kumar SA, Filipski SB et al (2013b) Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 18:1125–1135
66. Horder J, Harmer CJ, Cowen PJ et al (2010) Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol 13:1103–1113
67. Horti AG, Fan H, Kuwabara H et al (2006) 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 47:1689–1696
68. Huang YC, Wang SJ, Chiou LC et al (2003) Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci 23:10311–10320
69. Hungund BL, Vinod KY, Kassir SA et al (2004) Upregulation of CB1 receptors and agoniststimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 9:184–190
70. Ishiguro H, Horiuchi Y, Ishikawa M et al (2010) Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 67:974–982
71. Jacob W, Yassouridis A, Marsicano G et al (2009) Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 8:685–698
72. John CS, Currie PJ (2012) N-arachidonoyl-serotonin in the basolateral amygdala increases anxiolytic behavior in the elevated plus maze. Behav Brain Res 233:382–388
73. Juhasz G, Chase D, Pegg E et al (2009) CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 34:2019–2027
74. Kamprath K, Marsicano G, Tang J et al (2006) Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 26:6677–6686
75. Kamprath K, Plendl W, Marsicano G et al (2009) Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav 8:203–211
76. Kasckow JW, Mulchahey JJ, Geracioti TD Jr (2004) Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 28:291–295
77. Kathuria S, Gaetani S, Fegley D et al (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76–81
78. Kelly DL, Gorelick DA, Conley RR et al (2011) Effects of the cannabinoid-1 receptor antagonistrimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 31:86–91
79. Kerr DM, Downey L, Conboy M et al (2013) Alterations in the endocannabinoid system in the ratvalproic acid model of autism. Behav Brain Res 249:124–132
80. Kinsey SG, O’Neal ST, Long JZ et al (2011) Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98:21–27
81. Kiritoshi T, Sun H, Ren W et al (2013) Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1. Neuropharmacology 66:170–178
82. Koethe D, Llenos IC, Dulay JR et al (2007) Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114:1055–1063
83. Koethe D, Giuffrida A, Schreiber D et al (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194:371–372
84. Levin R, Peres FF, Almeida V et al (2014) Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. Front Pharmacol 5:10
85. Leweke FM, Giuffrida A, Wurster U et al (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665–1669
86. Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2, e94
87. Lin QS, Yang Q, Liu DD et al (2011) Hippocampal endocannabinoids play an important role in induction of long-term potentiation and regulation of contextual fear memory formation. Brain Res Bull 86:139–145
88. Lisboa SF, Resstel LB, Aguiar DC et al (2008) Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 593:73–78
89. Litvin Y, Phan A, Hill MN et al (2013) CB1 receptor signaling regulates social anxiety and memory. Genes Brain Behav 12:479–489
90. Maccarrone M, Valverde O, Barbaccia ML et al (2002) Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci 15:1178–1186
91. Marsch R, Foeller E, Rammes G et al (2007) Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 27:832–839
92. Marsicano G, Wotjak CT, Azad SC et al (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534
93. Martin M, Ledent C, Parmentier M et al (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159:379–387
94. McLaughlin RJ, Hill MN, Dang SS et al (2013) Upregulation of CB1 receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behav Brain Res 237:333–337
95. Melis M, Perra S, Muntoni AL et al (2004) Prefrontal cortex stimulation induces 2-arachidonoylglycerol- mediated suppression of excitation in dopamine neurons. J Neurosci 24:10707–10715
96. Meltzer HY, Arvanitis L, Bauer D et al (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975–984
97. Meye FJ, Trezza V, Vanderschuren LJ et al (2013) Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 18:1294–1301
98. Micale V, Cristino L, Tamburella A et al (2009) Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34:593–606
99. Mikics E, Vas J, Aliczki M et al (2009) Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav Pharmacol 20:265–272
100. Minocci D, Massei J, Martino A et al (2011) Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. J Affect Disord 134:427–430
101. Mitchell PB, Morris MJ (2007) Depression and anxiety with rimonabant. Lancet 370 (9600):1671–1672
102. Mitjans M, Serretti A, Fabbri C et al (2013) Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology (Berl) 227:509–519
103. Moise AM, Eisenstein SA, Astarita G et al (2008) An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berl) 200:333–346
104. Monteleone P, Bifulco M, Maina G et al (2010) Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 61:400–404
105. Moreira FA, Aguiar DC, Guimaraes FS (2007) Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 52:958–965
106. Moreira FA, Kaiser N, Monory K et al (2008) Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54:141–150
107. Muguruza C, Lehtonen M, Aaltonen N et al (2013) Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res 148:145–150
108. Naderi N, Haghparast A, Saber-Tehrani A et al (2008) Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 89:64–75
109. Naidu PS, Varvel SA, Ahn K et al (2007) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192:61–70
110. Navarro M, Hernandez E, Munoz RM et al (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491–496
111. Neumeister A, Normandin MD, Pietrzak RH et al (2013) Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18:1034–1040
112. Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172:556–560
113. O’Brien LD, Wills KL, Segsworth B et al (2013) Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav 103:597–602
114. Onaivi ES, Ishiguro H, Gong JP et al (2008) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 3, e1640
115. Ortega-Alvaro A, Aracil-Fernandez A, Garcia-Gutierrez MS et al (2011) Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 36:1489–1504
116. Parolaro D, Zamberletti E, Rubino T (2014) Cannabidiol/Phytocannabinoids: a new opportunity for schizophrenia treatment. In: Pertwee R (ed) Handbook of Cannabis. Oxford University Press edn, Oxford, pp 526–537
117. Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304–311
118. Perra S, Pillolla G, Luchicchi A et al (2008) Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system. Alcohol Clin Exp Res 32:443–449
119. Plendl W, Wotjak CT (2010) Dissociation of within- and between-session extinction of conditioned fear. J Neurosci 30:4990–4998
120. Potvin S, Joyal CC, Pelletier J et al (2008) Contradictory cognitive capacities among substanceabusing patients with schizophrenia: a meta-analysis. Schizophr Res 100:242–251
121. Realini N, Vigano’ D, Guidali C et al (2011) Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology 60:235–243
122. Reich CG, Taylor ME, McCarthy MM (2009) Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats. Behav Brain Res 203:264–269
123. Rey AA, Purrio M, Viveros MP et al (2012) Biphasic effects of cannabinoids in anxiety responses: CB1 and GABAB receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37:2624–2634
124. Robinson SA, Loiacono RE, Christopoulos A et al (2010) The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. Brain Res 1343:153–167
125. Rodgers RJ, Haller J, Halasz J et al (2003) ‘One-trial sensitization’ to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 17:1279–1286
126. Rodgers RJ, Evans PM, Murphy A (2005) Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 16:405–413
127. Roohbakhsh A, Keshavarz S, Hasanein P et al (2009) Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours. Basic Clin Pharmacol Toxicol 105:333–338
128. Rubino T, Realini N, Castiglioni C et al (2008a) Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18:1292–1301
129. Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P, Parolaro D. (2008b). CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 54, 151-160.
130. Rubino T, Realini N, Braida D et al (2009) The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 15:291–302
131. Rubio M, Fernandez-Ruiz J, De Miguel R et al (2008) CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcoholwithdrawal in rats. Neuropharmacology 54:976–988
132. Ruehle S, Rey AA, Remmers F et al (2012) The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 26:23–39
133. Sanchis-Segura C, Cline BH, Marsicano G et al (2004) Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 176:223–232
134. Santos CJ, Stern CA, Bertoglio LJ (2008) Attenuation of anxiety-related behavior after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. Behav Pharmacol 19:357–360
135. Scherma M, Medalie J, Fratta W, et al (2008) The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 54:129–140
136. Schubart CD, Sommer IE, van Gastel WA et al (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216–221
137. Sciolino NR, Zhou W, Hohmann AG (2011) Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64:226–234
138. Seifert J, Ossege S, Emrich HM et al (2007) No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci Lett 426:29–33
139. Seillier A, Advani T, Cassano T et al (2010) Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol 13:373–386
140. Seillier A, Martinez AA, Giuffrida A (2013) Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia. Neuropsychopharmacology 38:1816–1824
141. Shin LM, Liberzon I (2010) The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 35:169–191
142. Sink KS, McLaughlin PJ, Wood JA et al (2008) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946–955
143. Sink KS, Segovia KN, Collins LE et al (2010a) The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav 95:479–484
144. Sink KS, Segovia KN, Sink J et al (2010b) Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 20:112–122
145. Spano MS, Fadda P, Frau R et al (2010) Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur Neuropsychopharmacol 20:25–36
146. Steiner MA, Wanisch K, Monory K et al (2008) Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J 8:196–208
147. Terzian AL, Aguiar DC, Guimaraes FS et al (2009) Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur Neuropsychopharmacol 19:188–195
148. Thiemann G, Watt CA, Ledent C et al (2009) Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behav Brain Res 200:60–67
149. Trezza V, Campolongo P (2013) The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Front Behav Neurosci 7:100
150. Tsai SJ, Wang YC, Hong CJ (2000) Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr Genet 10:149–151
151. Ujike H, Takaki M, Nakata K et al (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7:515–518
152. Uriguen L, Perez-Rial S, Ledent C et al (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46:966–973
153. Uriguen L, Garci´a-Fuster MJ, Callado LF et al (2009) Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 206:313–324
154. Varga B, Kassai F, Gyertyan I (2012) Interactions of CB1 and mGLU5 receptor antagonists in food intake, anxiety and memory models in rats. Pharmacol Biochem Behav 103:425–430
155. Varvel SA, Lichtman AH (2002) Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301:915–924
156. Vetter S, Rossegger A, Rossler W et al (2008) Exposure to the tsunami disaster, PTSD symptoms and increased substance use - an Internet based survey of male and female residents of Switzerland. BMC Public Health 8:92
157. Viganó D, Guidali C, Petrosino S et al (2009) Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol 12:599–614
158. Vinod KY, Kassir SA, Hungund BL et al (2010) Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J Psychiatr Res 44:591–597
159. Vinod KY, Xie S, Psychoyos D et al (2012) Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats. PLoS One 7, e36743
160. Viveros M, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331–342
161. Volk DW, Eggan SM, Horti AG et al (2014) Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophr Res 159:124–129
162. Wong DF, Kuwabara H, Horti AG et al (2010) Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C] OMAR. Neuroimage 52:1505–1513
163. Zamberletti E, Viganó D, Guidali C et al (2010) Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int J Neuropsychopharmacol 15:267–280
164. Zamberletti E, Piscitelli F, Cadeddu F et al (2012a) Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. Br J Pharmacol 167:1652–1664
165. Zamberletti E, Rubino T, Parolaro D (2012b) The endocannabinoid system and schizophrenia: integration of evidence. Curr Pharm Des 18:4980–4990
166. Zammit S, Spurlock G, Williams H et al (2007) Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 191:402–407
167. Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355–360
168. Zhong P, Wang W, Pan B et al (2014) Monoacylglycerol lipase inhibition blocks chronic stressinduced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 39:1763–1776